Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to Sell at BidaskClub

BidaskClub lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a sell rating in a report published on Monday morning, BidAskClub reports.

Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Supernus Pharmaceuticals from a hold rating to a buy rating and set a $44.00 price objective for the company in a research report on Wednesday, March 13th. B. Riley set a $65.00 price objective on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Monday, March 4th. Cantor Fitzgerald set a $60.00 price objective on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, May 8th. Mizuho reiterated a buy rating and set a $63.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, April 17th. Finally, ValuEngine cut Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $55.57.

Shares of SUPN stock opened at $31.69 on Monday. Supernus Pharmaceuticals has a fifty-two week low of $29.60 and a fifty-two week high of $61.25. The stock has a market capitalization of $1.57 billion, a PE ratio of 15.46, a P/E/G ratio of 1.01 and a beta of 1.67. The firm has a fifty day moving average price of $32.27. The company has a current ratio of 2.77, a quick ratio of 2.59 and a debt-to-equity ratio of 0.75.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.10). The firm had revenue of $85.50 million during the quarter, compared to analysts’ expectations of $102.26 million. Supernus Pharmaceuticals had a net margin of 25.49% and a return on equity of 23.60%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.49 EPS. Analysts forecast that Supernus Pharmaceuticals will post 2.25 EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Supernus Pharmaceuticals by 0.9% in the 4th quarter. BlackRock Inc. now owns 8,075,659 shares of the specialty pharmaceutical company’s stock worth $268,272,000 after buying an additional 72,658 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in Supernus Pharmaceuticals by 9.5% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,000,381 shares of the specialty pharmaceutical company’s stock worth $35,053,000 after buying an additional 86,645 shares during the last quarter. Fiera Capital Corp boosted its stake in Supernus Pharmaceuticals by 6.0% in the 4th quarter. Fiera Capital Corp now owns 941,530 shares of the specialty pharmaceutical company’s stock worth $31,277,000 after buying an additional 53,404 shares during the last quarter. Ashford Capital Management Inc. boosted its stake in Supernus Pharmaceuticals by 7.3% in the 4th quarter. Ashford Capital Management Inc. now owns 750,276 shares of the specialty pharmaceutical company’s stock worth $24,924,000 after buying an additional 50,844 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its stake in Supernus Pharmaceuticals by 31.4% in the 4th quarter. Macquarie Group Ltd. now owns 747,044 shares of the specialty pharmaceutical company’s stock worth $24,817,000 after buying an additional 178,682 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Read More: Book Value Per Share – BVPS

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.